January 2019 in “Figshare” Intralesional corticosteroids are best for mild alopecia areata, and DPCP is best for severe cases.
1 citations
,
June 2024 in “Journal of Investigative Dermatology” Macrophages are crucial for hair regrowth in contact hypersensitivity.
22 citations
,
March 1999 in “International Journal of Clinical Practice” Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.
5 citations
,
July 1988 in “British journal of dermatology/British journal of dermatology, Supplement” Diphencyprone therapy can effectively treat severe hair loss in motivated patients.
37 citations
,
September 2009 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Diphencyprone (DPC) is an effective and safe long-term treatment for alopecia areata, especially with maintenance therapy.
9 citations
,
April 2016 in “Australasian journal of dermatology” Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.
28 citations
,
September 2014 in “Journal of Veterinary Internal Medicine” VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.
58 citations
,
May 2004 in “British Journal of Dermatology” Diphenylcyclopropenone treatment helps hair growth in alopecia areata by promoting blood vessel growth and cell survival.
4 citations
,
August 2013 in “Case reports in dermatology” A patient with total hair loss developed vitiligo after using a treatment called DCP.
18 citations
,
January 2021 in “Theranostics” The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
27 citations
,
December 2015 in “Clinical and Experimental Dermatology” Diphencyprone helped most patients with alopecia areata regrow some hair.
20 citations
,
October 2003 in “The Journal of Dermatology” DCP therapy causes side effects like weakness, flushing, headaches, and taste changes, but less frequently causes hypertension and diabetes.
1 citations
,
December 2023 in “Nanomaterials” Combining specific nanoparticles with immune therapy significantly improves cancer treatment.
March 2005 in “Journal of The American Academy of Dermatology” Diphencyprone treatment protocols could be simplified as no harm occurred despite not fully following them.
11 citations
,
January 2009 in “Indian journal of dermatology, venereology, and leprology” DCPA is a chronic skin condition affecting the lower limbs, mainly in men, with unclear causes and treatments that often don't work well.
July 2025 in “Ultrasound in Medicine & Biology” 8 citations
,
January 1977 in “Acta Haematologica” The treatment was effective for advanced non-Hodgkin's lymphomas.
2 citations
,
November 2024 in “JAAD Case Reports” October 2017 in “Our Dermatology Online” DCP in isopropanol is better tolerated for treating alopecia areata.
1 citations
,
April 2020 in “Journal of the Endocrine Society” Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.
January 2010 in “Journal of Animal Science” Transcutaneous vaccination using nanoparticles can enhance immune responses and reduce basal cell carcinomas.
18 citations
,
December 2016 in “European journal of pharmacology” A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.
2 citations
,
October 2023 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Dupilumab significantly improved a 5-year-old girl's prurigo nodularis without side effects.
4 citations
,
November 2016 in “Journal of Cutaneous Pathology” Three characteristics of plasmacytoid dendritic cells help tell apart lupus-related hair loss from LPP.
April 2024 in “Canadian Journal of Ophthalmology” A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
January 2024 in “Wiadomości Lekarskie” DEC cells show promise as a safe and effective treatment for Duchenne muscular dystrophy.
Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.